Does it Matter Whether Canada's Separate Health Technology Assessment Process for Cancer Drugs has an Economic Rationale?

Pharmacoeconomics. 2015 Aug;33(8):879-82. doi: 10.1007/s40273-015-0278-7.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antineoplastic Agents / economics
  • Antineoplastic Agents / therapeutic use*
  • Canada
  • Humans
  • Neoplasms / drug therapy*
  • Neoplasms / economics
  • Technology Assessment, Biomedical / methods*

Substances

  • Antineoplastic Agents